Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
21 nov. 2024 08h19 HE
|
Biomerica, Inc.
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The...
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
07 nov. 2024 08h00 HE
|
Phathom Pharmaceuticals
Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increaseOver 143,000 prescriptions filled for...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
04 nov. 2024 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
28 oct. 2024 08h00 HE
|
Phathom Pharmaceuticals
Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
27 oct. 2024 12h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
29 août 2024 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 08h00 HE
|
Phathom Pharmaceuticals
Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second...
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
30 juil. 2024 08h00 HE
|
Phathom Pharmaceuticals
CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies for its more than 26 million commercially insured...
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
29 juil. 2024 07h59 HE
|
Phathom Pharmaceuticals
Management to host conference call on Thursday, August 8, 2024, at 8:30 am ET FLORHAM PARK, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
18 juil. 2024 08h00 HE
|
Phathom Pharmaceuticals
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD)